CLEAR CELL RENAL CELL CARCINOMA

This study tests whether adding the experimental drug SLC-3010 to the standard drug axitinib works better than axitinib alone for people with advanced clear cell kidney cancer that has worsened after first treatment. About 78 adults will be randomly assigned to one of the two gro…

This study tests whether giving belzutifan alone, pembrolizumab alone, or both together before surgery can help control advanced clear cell kidney cancer. About 10 participants with locally advanced disease will receive one of these treatments before partial or total kidney remov…

This early-phase study tests a new drug called NN3201, designed to find and attack cancer cells that have a specific protein called c-Kit. The trial includes people with advanced or spreading cancers like gastrointestinal stromal tumors (GIST), small-cell lung cancer, and others.…

This study tests whether the drug belzutifan can help control metastatic clear cell kidney cancer in people whose cancer is slow-growing and who would normally just be watched. About 78 adults with no prior treatment will either take belzutifan or continue active surveillance. Th…

This study tests a new drug, MGC026, in 250 adults with advanced solid tumors that have not responded to other treatments. The goal is to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants receive the drug by IV and are closely monitored f…

This study tests two immunotherapy drugs (cemiplimab and fianlimab) given after targeted radiation in people with kidney cancer that has spread to a few spots in the body. The goal is to see if the drug combination can keep the cancer from growing for at least a year. About 72 ad…

This study tests whether a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus a targeted therapy (lenvatinib) can shrink kidney tumors enough to allow safe, kidney-sparing surgery in patients who otherwise would need full kidney removal. About 25 adults wi…

This early-stage study tests an experimental drug called XmAb819 in people with advanced clear cell kidney cancer that has not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 307 participants will receive the drug intrav…

This study is for people with high-risk kidney cancer that has been removed by surgery. It compares the usual immunotherapy drug (pembrolizumab) alone versus the same drug plus a targeted therapy (tivozanib). The goal is to see if the combination works better at preventing the ca…

This study tests a new medicine, PF-08634404, in adults with advanced kidney cancer that has spread. The goal is to see if it is safe and can shrink tumors when given alone or with other cancer drugs. About 224 participants will receive the drug through an IV. This is an early-ph…

This study tests a new drug called zanzalintinib, alone or with an immunotherapy (nivolumab), in people with advanced kidney cancer that got worse after standard first treatment. About 70 adults will take part. The goal is to see if the combination can shrink tumors or slow the d…

This early-phase study tests a new drug called casdatifan (AB521) in people with advanced kidney cancer or other solid tumors that haven't responded to standard treatments. The goal is to find safe doses and see how well the drug works alone or combined with other cancer therapie…

This early-phase study tests a new drug called NEO-811 in about 30 people with advanced clear cell kidney cancer that cannot be removed by surgery. The main goals are to find a safe dose and check for side effects. Participants must have tried or refused standard treatments.

This study tests a combination of three drugs—177Lu girentuximab, cabozantinib, and nivolumab—in people with advanced clear cell kidney cancer who have not had treatment before. The goal is to see if this mix can help control the cancer. About 100 adults will take part, and the s…

This study is looking for a better way to diagnose clear cell kidney cancer. Right now, doctors use scans and sometimes a biopsy, which can be expensive and invasive. The researchers are testing if tiny particles called exosomes, which are shed by cancer cells into urine, can be …

This study tests a special PET/CT scan that may help doctors see kidney cancer more clearly. It is not a treatment—its goal is to learn how well the scan shows cancer activity. About 35 adults with kidney cancer will take part. The scan results will be compared with tissue sample…